BNOX Overview

Trading Halt: Bionomics (BNOX) Ltd – ADR has had its trading halted due to pending news.

Recent Developments: The company has made strategic shifts, including a Supreme Court-approved re-domiciliation and the publication of results from a Phase 2 study of BNC210.

Neuphoria Therapeutics Update: Neuphoria Therapeutics Inc. has successfully completed its redomiciliation from Bionomics, establishing itself as the successor issuer with new governance documents and registered shares under the Exchange Act.

Bionomics Stock Performance: Bionomics (BNOX) has experienced a significant year-to-date price drop of 83.65%, with a current market cap of $4.72 million and a consensus rating of "Buy" based on average trading volume of approximately 9.7 million shares.

Bionomics Re-domiciliation: Bionomics Limited has received court approval for its re-domiciliation from Australia to the United States, with Neuphoria Therapeutics Inc. becoming the new parent company effective December 23, 2024.

Trading Information: Bionomics' American Depositary Shares (ADSs) will continue trading on Nasdaq until the implementation date, and shares of Neuphoria are expected to start trading under the symbol "NEUP" on December 24, 2024.

Bionomics Shareholder Approval: Bionomics Limited has received approval from 96% of its shareholders for a proposed re-domiciliation to the United States, where Neuphoria Therapeutics Inc. will become the parent company.

Next Steps and Conditions: The implementation of the Scheme is subject to several conditions, including court approval in Australia, with an expected completion date around December 24, 2024, when shares of Neuphoria are anticipated to begin trading on Nasdaq.

BNC210 Efficacy in PTSD: Bionomics Limited reported positive results from its Phase 2 ATTUNE study, showing that BNC210 significantly improved PTSD symptoms at Week 12, with effects noted as early as Week 4.

Future Plans for Clinical Trials: The company plans to initiate a Phase 3 study of BNC210 for PTSD in the second half of 2025, while also evaluating it in a separate Phase 3 trial for social anxiety disorder.

Bionomics Presentation Announcement: Bionomics Limited will present the results of its Phase 2 ATTUNE trial for BNC210, a treatment for post-traumatic stress disorder (PTSD), at the American College of Neuropsychopharmacology's annual meeting on December 8, 2024.

Company Overview: Bionomics is a clinical-stage biotechnology company focused on developing innovative treatments for central nervous system disorders, with BNC210 being its lead candidate for social anxiety disorder and PTSD.